1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine fumarate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine fumarate
• 英文别名: (E)-but-2-enedioic acid;5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
• 化学式: C₄H₄O₄*C₂₂H₃₀N₆O₄S
• 分子量: 590.657
• InChiKey: PJBXAYPWQLGGJS-WLHGVMLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.32
• 重原子数：
  41
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  192
• 氢给体数：
  3
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  富马酸 、 西地那非 以 乙醇 、 乙腈 为溶剂， 反应 14.0h， 生成 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine fumarate
  参考文献：
  名称：

  WO2007/110559

  摘要：

  公开号：

文献信息

• [EN] NEW PHARMACEUTICAL FORMS OF SILDENAFIL<br/>[FR] NOUVELLES FORMES PHARMACEUTIQUES DU SILDÉNAFIL
  申请人：N4 PHARMA UK LTD

  公开号：WO2017168174A1

  公开（公告）日：2017-10-05

  The invention provides a pharmaceutical composition comprising sildenafil or a pharmaceutically acceptable salt thereof admixed with excipients in a multicomponent pharmaceutical composition, wherein a first component is adapted to deliver sildenafil rapidly to promote fast onset of action, and a further component is adapted to deliver the sildenafil from dose to dose, wherein the sildenafil is delivered from dose to dose within the therapeutic window.

  这项发明提供了一种药物组合物，包括硝苯地平或其药用可接受的盐与赋形剂混合在一个多成分的药物组合物中，其中第一个成分被设计用于快速释放硝苯地平以促进快速起效，另一个成分被设计用于从一剂到另一剂地释放硝苯地平，硝苯地平在治疗窗口内从一剂到另一剂被释放。
• [EN] SAA DERIVATIVE COMPOUND RESTORES ENOS AND INHIBITS OXIDATIVE STRESS-INDUCED DISEASES IN HYPOXIA<br/>[FR] COMPOSÉ DÉRIVÉ DE SAA PERMETTANT LE RÉTABLISSEMENT DE L'ENOS ET INHIBANT LES AFFECTIONS INDUITES PAR LE STRESS OXYDATIF DANS L'HYPOXIE
  申请人：JANSFAT BIOTECHNOLOGY CO LTD

  公开号：WO2015161510A1

  公开（公告）日：2015-10-29

  The Substituted Amine Analogs (SAA) derivative compounds and SAA complex compounds disclosed are characterized as compositions having the functions of inhibiting disorders caused by oxidative stress, and more particularly to those SAA derivative compounds capable of inhibiting disorders caused by oxidative stress consisting of neurodegenerative diseases, lung diseases, oxidative stress-induced heart disease and carvenosus dysfunction.

  所披露的取代胺类似物（SAA）衍生物化合物和SAA复合物化合物被描述为具有抑制由氧化应激引起的疾病的功能的组合物，更特别地是那些能够抑制由氧化应激引起的神经退行性疾病、肺部疾病、氧化应激诱导的心脏疾病和心脏功能障碍的SAA衍生物化合物。
• SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia
  申请人：JANSFAT BIOTECHNOLOGY CO., LTD.

  公开号：US20150306107A1

  公开（公告）日：2015-10-29

  The Substituted Amine Analogs (SAA) derivative compounds and SAA complex compounds disclosed in the present invention are characterized as compositions having the functions of inhibiting disorders caused by oxidative stress, and more particularly to those SAA derivative compounds capable of inhibiting disorders caused by oxidative stress because of neurodegenerative diseases, lung diseases, oxidative stress-induced heart disease and carvenosus dysfunction.

  本发明揭示的取代胺类似物（SAA）衍生物化合物和SAA复合物化合物的特征是具有抑制氧化应激引起的疾病的功能，更特别地，是那些能够抑制由于神经退行性疾病、肺部疾病、氧化应激引起的心脏疾病和海绵体功能障碍引起的疾病的SAA衍生物化合物。
• Pharmaceutical composition of sildenafil and a large conductance Ca(2+) activated K+ channels activator
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1652521A1

  公开（公告）日：2006-05-03

  The present invention refers to a pharmaceutical composition of sildenafil and a large conductance Ca(2+) activated K+ channels activator and its use for the treatment of sexual dysfunction in man and woman, sexual disorders in man, erectile dysfunction or impotence.

  本发明涉及一种由西地那非和一种大电导 Ca(2+) 活化 K+ 通道激活剂组成的药物组合物，及其用于治疗男女性功能障碍、男性性障碍、勃起功能障碍或阳痿的用途。
• Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1676573A1

  公开（公告）日：2006-07-05

  The present invention relates to a pharmaceutical composition comprising a 2,5-dihydroxybenzenesulfonic compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor, a medicament comprising said pharmaceutical composition as well as the use of said pharmaceutical composition for the manufacture of a medicament.

  本发明涉及一种由 2,5-二羟基苯磺酸化合物、钾离子通道调节剂和 5 型磷酸二酯酶抑制剂组成的药物组合物，一种包含所述药物组合物的药品，以及使用所述药物组合物制造药品。